{"id":910776,"date":"2025-11-17T09:57:48","date_gmt":"2025-11-17T14:57:48","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-provides-corporate-update-and-reports-first-quarter-2025-26-results\/"},"modified":"2025-11-17T09:57:48","modified_gmt":"2025-11-17T14:57:48","slug":"propanc-biopharma-provides-corporate-update-and-reports-first-quarter-2025-26-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/propanc-biopharma-provides-corporate-update-and-reports-first-quarter-2025-26-results\/","title":{"rendered":"Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025\/26 Results"},"content":{"rendered":"
\n

MELBOURNE, Australia, Nov. 17, 2025 (GLOBE NEWSWIRE) — Propanc Biopharma, Inc. (Nasdaq: PPCB) (\u201cPropanc\u201d or the \u201cCompany\u201d), a biopharmaceutical company developing novel treatments for recurrent and metastatic cancer, today announced an update on corporate progress and reported financial results for the first quarter ended September 30, 2025 (Year end June 30).<\/p>\n

\n Corporate and R&D Highlights<\/strong>\n <\/p>\n

\n Advancing PRP Toward Phase 1b First-in-Human Trial (2026)<\/strong>\n <\/p>\n

Propanc continues to advance its lead candidate, PRP, toward a world-first Phase 1b clinical study in 30\u201340 patients with advanced solid tumors at the Peter Mac Cancer Center in Melbourne. GMP manufacturing scale-up, analytical method validation, and preparation of the Investigator\u2019s Brochure and Clinical Trial Application are underway. Purification processes have been successfully scaled, delivering >95% purity to pharmaceutical standards. Two related patents are in drafting.<\/p>\n

\n Progressing Rec-PRP Synthetic Program<\/strong>\n <\/p>\n

Rec-PRP, a fully synthetic recombinant version of PRP designed for improved stability and global scalability, is undergoing biological validation against the bovine-derived formulation. Supporting research has identified methods enabling large-scale production, with patent drafting in progress. Rec-PRP will enter formal preclinical development following potency evaluation.<\/p>\n

\n POP1 Joint Research Program Extension<\/strong>\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0<\/p>\n

Propanc is negotiating a 12-month extension with the Universities of Ja\u00e9n and Granada to expand the POP1 research program. Recent findings show PRP significantly reduces tumorigenicity in Gemcitabine-resistant pancreatic cancer and modulates malignant cells toward a less aggressive phenotype. Additional patents are being prepared based on these results.<\/p>\n

\n Corporate and Financial Updates<\/strong>\n <\/p>\n

\n Nasdaq Listing & Public Offering<\/strong>\n <\/p>\n

The Company closed an underwritten public offering of 1,000,000 shares at $4.00 per share, raising gross proceeds of $4 million. Propanc\u2019s common stock began trading on the Nasdaq Capital Market on August 15.<\/p>\n

\n $100 Million Private Placement Facility<\/strong>\n <\/p>\n

Propanc entered into a private placement agreement for up to $100 million to accelerate clinical development. The Company received an initial $1 million investment upon issuance of 100 shares of Series C Convertible Preferred Stock.<\/p>\n

\n Q1 Financial Summary (Quarter Ended September 30, 2025)<\/strong>\n <\/p>\n